Key result
EV-ICD shows similar freedom from major system complications in older versus younger patients.
Why the study?
Implanters have often chosen the EV-ICD for younger patients to avoid long transvenous lead dwell times, warranting an assessment of EV-ICD outcomes in older patients.
Does the extravascular implantable cardioverter-defibrillator (EV-ICD) have comparable safety and efficacy in older (≥65 years) versus younger (<65 years) patients?
Cohort (n=786)
Yes
Does the extravascular implantable cardioverter-defibrillator (EV-ICD) have comparable safety and efficacy in older (≥65 years) versus younger (<65 years) patients?
The extravascular ICD demonstrates comparable mid-term safety and efficacy in older (≥65 years) and younger patients in a real-world registry.
Answers are grounded in this paper and cite their sources.
Similar complication freedom across ages; leaves open whether age affects device safety in broader populations.
Background The extravascular implantable cardioverter-defibrillator (EV-ICD) avoids vascular lead placement by implanting a lead in the substernal space. To date, implanters have often chosen the EV-ICD for younger patients, presumably to avoid the risks associated with long transvenous lead dwell times. Thus, an assessment of the EV-ICD in older patients is warranted. Purpose This analysis aims to examine outcomes of the EV-ICD in older patients (≥65) and compare to younger patients (<65) using data from a large, real-world, post-approval registry. Methods Enlighten is a global, prospective, post-market, registry study enrolling patients implanted with an EV-ICD system and following them for the life of the device. The primary endpoint of the Enlighten study is freedom from chronic (>30 days), system-related major complications at five years, excluding infections. Patients with an implant attempt were split into two groups based on their age at implant: those <65 years of age and those ≥65 years of age. Procedure outcomes, safety (including the primary endpoint at 6 months and infections), and characterization of appropriate and inappropriate therapy were assessed for each group. Results Patients aged ≥65 (N=135; mean age: 70.5±4.5 years) differed from those aged <65 (N=651; mean age: 44.6±12.6 years), with the older cohort having a lower proportion of women (20.7% vs 30.3% female), a lower mean LVEF (41.3±15.9% vs 45.5±16.0%), higher proportion of secondary prevention (37.0% vs 33.5%), and more likely to have a history of AF (28.9% vs 10.8%). Tunneling and lead placement success rate (100% vs 99.1%; P=0.60) and defibrillation testing success rate (100% vs 98.8%; P=0.60) were comparable in older and younger patients, respectively. The primary endpoint, evaluated at 6 months, did not differ: there was a 98.1% and 97.7% freedom from chronic, major system-related complications in older and younger patients, respectively (P=0.72). Of 11 major system- and/or procedure-related infections that occurred, 10 (1.5%) were in those <65 and one (0.7%) among those ≥65 through all follow-up. The older cohort also had statistically insignificant lower rates of appropriate therapy (2.1% vs 5.8%; P=0.31) and inappropriate shock (3.9% vs 5.8%; P=0.39) compared to the younger cohort, through 6 months. Conclusions In a large, real-world cohort through a mid-term observation period, the EV-ICD safety and efficacy was at least as good for older as it was for younger recipients of the system. These preliminary data indicate that the EV-ICD represents a clinically important option for all adults who are indicated for an ICD and do not require pacing.
No takes yet. Share an insight, caveat, or question.
Duncker et al. (2026) conducted a cohort in Indication for implantable cardioverter-defibrillator without pacing requirement (n=786). EV-ICD in patients ≥65 years vs. EV-ICD in patients <65 years was evaluated on Freedom from chronic (>30 days), system-related major complications, excluding infections (p=0.72).
Synapse has enriched 10 related papers. Consider them for comparative context: